Precise sample metering method by coordinated burst action of hydrophobic burst valves applied to dried blood spot collection
Vloemans et al.
The finding, in our words
A microfluidic DBS device using hydrophobic burst valves meters 5-15 μL blood accurately across 25-70% haematocrit and, in a therapeutic drug monitoring validation with adalimumab-spiked samples, achieves higher recovery than traditional DBS (86% versus 62%), supporting precise home or low-resource sampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The HematoCARD cartridge autonomously collects duplicate 10 microlitre dried blood spot samples from a single finger prick and shows good analytical performance for monitoring adalimumab, with accuracy between 91 and 111 per cent, linearity R squared 0.99 and coefficient of variation at or above 0.94 compared with serum reference and commercial DBS microsampling methods.
An LC-MS/MS method for dried blood spots simultaneously quantifies four therapeutic monoclonal antibodies and estimates haematocrit from haemoglobin peptides with >0.9 correlation to laboratory values, enabling accurate therapeutic drug monitoring from self-collected samples for decentralised care.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Deprez et al. validated LC‑MS/MS methods for four immunosuppressants and creatinine from a single 10 μL quantitative dried blood spot. With biases under 10 % and CVs below 8 %, the approach enables accurate patient‑centric therapeutic drug monitoring from capillary blood at home, mitigating the haematocrit effect through volumetric collection.
A review of VAMS and DBS microsampling for TDM of therapeutic monoclonal antibodies, adalimumab, infliximab and others, in inflammatory disease: a convenient, home-friendly alternative to venepuncture that can preserve analytical accuracy, subject to assay-specific validation.